1cP-AL-LAD - PsychonautWiki


Summary sheet: 1cP-AL-LAD
Chemical Nomenclature
Common names 1cP-AL-LAD
Substitutive name 1-Cyclopropionyl-6-allyl-6-nor-lysergic acid diethylamide
Systematic name (6aR,9R)1-Cyclopropionyl-N,N-diethyl-7-(prop-2-en-1-yl)-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide
Class Membership
Psychoactive class Psychedelic
Chemical class Lysergamide
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 20 µg
Light 50 - 100 µg
Common 100 - 225 µg
Strong 225 - 350 µg
Heavy 350 µg +
Total 7 - 10 hours
Onset 20 - 60 minutes
Come up 30 - 60 minutes
Peak 2.5 - 5 hours
Offset 2 - 3 hours
After effects 2 - 18 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


1-Cyclopropionyl-6-allyl-6-nor-lysergic acid diethylamide (also known commonly as 1cP-AL-LAD) is a novel psychedelic substance of the lysergamide class. 1cP-AL-LAD is closely related to AL-LAD, for which it is suspected to be a prodrug for, but there is currently no data or much anecdotal reports to confirm this.

1cP-AL-LAD is a novel research chemical which has probably first been produced by a small group of chemists which have also synthesized various other novel lysergamdîdes at the time alongside like 1cP-MiPLA, LSZ and LST in 2020 or 2021.[citation needed] There is very little proof for the validity of this claim.

User reports describe the effects of 1cP-AL-LAD as similar to those of AL-LAD. Some anecdotal reports state that there could be a notable, if even slight, difference between the two although this does not indicate that that it isn't a true prodrug for AL-LAD. Many effects seem to be identical or nearly identical, including a more manageable and lucid mental state, apparent visuals and dosage levels.

Very little data exists about the pharmacological properties, metabolism, and toxicity of 1cP-AL-LAD. While it is often characterized by users as being generally more recreational and non-threatening compared to LSD, it is highly advised to approach this highly potent hallucinogenic substance with the proper amount of precaution and harm reduction practices if using it.


1cP-AL-LAD, or 1-Cyclopropionyl-6-allyl-6-nor-lysergic acid diethylamide, is a semisynthetic alkaloid of the lysergamide family. 1cP-AL-LAD is a structural analog of lysergic acid, with an N,N-diethylamide functional group bound to RN of the chemical structure. 1cP-AL-LAD's chemical structure contains a bicyclic hexahydroindole fused to a bicyclic quinoline group (nor-lysergic acid). Unlike LSD, 1cP-AL-LAD does not contain a methyl group substituted at R6 of its nor-lysergic acid skeleton, this is represented by the nor- prefix. Instead, 1cP-AL-LAD is substituted at R6 with an allyl group comprised of a methylene bridge bound to a vinyl substituent. It is also substituted at R1 with a Cyclopropionyl substituent. At carbon 8 of the quinoline a N,N-diethyl carboxamide is bound.

1cP-AL-LAD is a chiral compound with two stereocenters at R5 and R8. 1cP-AL-LAD, also called (+)-D-1cP-AL-LAD , has an absolute configuration of (5R, 8R). The three other stereoisomers of 1cP-AL-LAD presumably do not have psychoactive properties.[citation needed]


Further information: Serotonergic psychedelic

1cP-AL-LAD likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from 1cP-AL-LAD's efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain an object of scientific elucidation.

1cP-AL-LAD is also suspected to be a prodrug for AL-LAD, given its 1-Cyclopropionyl substitution. This can be compared with 1cP-LSD, which is also likely a prodrug for LSD. However there is not enough data, anecdotes or guarantees that this will be the exact same property of 1cP-AL-LAD.

1cP-AL-LAD also shares many common traits with its parent compound LSD; in humans, it appears to be roughly equal (or less) in potency as well as similar in mechanism although the progression and duration of effects are compressed (while remaining qualitatively less intense and more manageable - perhaps due to being catabolised more readily).

Subjective effects

While its subjective effects largely overlap with those of AL-LAD or LSD, 1cP-AL-LAD is commonly reported to be significantly shorter in its duration and less uncomfortable in both its negative physical side effects and general anxiety. Some users have proposed that this compound could potentially serve as an effective introductory psychedelic, alongside other shorter-lasting and manageable psychedelics like 2C-B or 4-HO-MET.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Cognitive effects

Multi-sensory effects

Combination effects

  • Alcohol - Alcohol's central depressant effects can counteract some of the anxiety and bodily tension produced by 1cP-AL-LAD. However, alcohol can cause dehydration, nausea and physical fatigue which can negatively impact the tone of the trip. Users are advised to pace themselves and drink a portion of their usual amount.
  • Benzodiazepines - Benzodiazepines are highly effective at reducing the intensity of 1cP-AL-LAD's effects through the general suppression of brain activity.
  • Cannabis - Cannabis strongly intensifies the sensory and cognitive effects of 1cP-AL-LAD. Extreme caution is advised when using this combination as it can significantly increase the chances of a negative psychological reaction like anxiety, confusion and psychosis. Users are advised to start off with only a fraction of their usual cannabis dose and take long breaks between hits to avoid over intake.
  • Dissociatives - 1cP-AL-LAD enhances the cognitive, visual and general hallucinatory effects of dissociatives. Dissociative-induced holes, spaces, and voids and internal hallucinations become more vivid and intense on 1cP-AL-LAD. These effects correspond with an increased risk of confusion, delusions, and psychosis.
  • MDMA - 1cP-AL-LAD and MDMA are highly synergistic and mutually enhance each other's physical, cognitive, and visual effects. The synergy between these substances is unpredictable so it is advised to start with markedly lower doses than one would take for each individually. There is some evidence that suggests that co-administration of LSD with MDMA increases the neurotoxicity of the latter,[1][2][3] and this may extend to 1cP-AL-LAD.

Experience reports

There are currently 0 anecdotal reports which describe the effects of this compound within our experience index.

Toxicity and harm potential

The toxicity and long-term health effects of recreational 1cP-AL-LAD use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 1cP-AL-LAD is a research chemical with very little history of human usage.

The body of anecdotal reports suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

As with other psychedelic substances, there are relatively few physical side effects that have been reported associated with acute 1cP-AL-LAD exposure. Although no formal studies have been conducted, it is likely that as with LSD itself, 1cP-AL-LAD is able to be considered non-addictive, with an extremely low toxicity relative to dose.[4] It is also likely that as with LSD, there are little to no negative physical, cognitive, psychiatric or other toxic consequences associated with acute 1cP-AL-LAD exposure.

However, as with LSD and psychedelics in general, it is possible that 1cP-AL-LAD can act as a potential trigger for those with underlying psychiatric conditions. Those with a personal or family history of mental illness are generally advised not to use this substance, particularly outside of a supervised medical setting.

It is strongly recommended that one uses harm reduction practices when using this substance.

Tolerance and addiction potential

Although no formal studies have been conducted, it is not unreasonable to assume that as with LSD itself, 1cP-AL-LAD is not habit-forming and that the desire to use it can actually decrease with use.

Tolerance to the effects of 1cP-AL-LAD is built almost immediately after ingestion. After that, it takes about 5-7 days for the tolerance to be reduced to half and 14 days to be back at baseline (in the absence of further consumption). 1cP-AL-LAD presents cross-tolerance with all psychedelics, meaning that after the use of 1cP-AL-LAD all psychedelics will have a reduced effect.


The LD50 of 1cP-AL-LAD is unknown. Adverse psychological reactions are common especially at higher dosages. Some of these include anxiety, delusions, panic attacks and more rarely seizures. Medical attention is usually only needed if suspected of severe psychotic episodes or “fake acid” (such as 25i-NBOMe or DOB). Administration of benzodiazepines or antipsychotics can help to relieve the negative cognitive effects of 1cP-AL-LAD.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Legal status

1cP-AL-LAD is currently a gray area compound within many parts of the world. This means that it is not known to be specifically illegal within most countries, but people may still be charged for its possession under certain circumstances such as under analog laws and with the intent to sell or consume.

  • Austria: 1cP-AL-LAD is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.[citation needed]
  • Germany: 1cP-AL-LAD is illegal in Germany as of July 2021.[citation needed]
  • Switzerland: 1cP-AL-LAD can be considered a controlled substance as a defined derivative of Lysergic Acid under Verzeichnis E point 263. It is legal when used for scientific or industrial use.[6]
  • United States: 1cP-AL-LAD is unscheduled but can be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.[citation needed]

See also

External links


  1. Armstrong, B. D.; Paik, E.; Chhith, S.; Lelievre, V.; Waschek, J. A.; Howard, S. G. (2004). "Potentiation of (DL)‐3,4‐methylenedioxymethamphetamine (MDMA)‐induced toxicity by the serotonin 2A receptior partial agonist d‐lysergic acid diethylamide (LSD), and the protection of same by the serotonin 2A/2C receptor antagonist MDL 11,939". Neuroscience Research Communications. 35 (2): 83–95. doi:10.1002/nrc.20023. ISSN 1520-6769. 
  2. Gudelsky, Gary A.; Yamamoto, Bryan; Nash, J. Frank (1994). "Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists". European Journal of Pharmacology. 264 (3): 325–330. doi:10.1016/0014-2999(94)90669-6. ISSN 0014-2999. 
  3. Capela, J. P.; Fernandes, E.; Remião, F.; Bastos, M. L.; Meisel, A.; Carvalho, F. (2007). "Ecstasy induces apoptosis via 5-HT2A-receptor stimulation in cortical neurons". Neurotoxicology. 28 (4): 868–875. doi:10.1016/j.neuro.2007.04.005. ISSN 0161-813X. PMID 17572501. 
  4. Passie, T.; Halpern, J. H.; Stichtenoth, D. O.; Emrich, H. M.; Hintzen, A. "The Pharmacology of Lysergic Acid Diethylamide: A Review" (PDF). CNS Neuroscience & Therapeutics. 14: 295–314. doi:10.1111/j.1755-5949.2008.00059.x. ISSN 1755-5930. Archived from the original (PDF) on May 1, 2013. Retrieved January 1, 2020. 
  5. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039. 
  6. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel,psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien: Änderung vom 2. November 2015" (PDF) (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.